Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

<p><strong>Background:</strong><br /> Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrex...

書誌詳細
主要な著者:	Nash, P, Mease, PJ, Fleishaker, D, Wu, J, Coates, LC, Behrens, F, Gladman, DD, Kivitz, AJ, Wei, JC, Shirinsky, I, Menon, S, Romero, AB, Fallon, L, Hsu, MA, Wang, C, Kanik, KS
フォーマット:	Journal article
言語:	English
出版事項:	Elsevier 2020

類似資料

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
著者:: Nash, P, 等
出版事項: (2021)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
著者:: Peter Nash, 等
出版事項: (2020-06-01)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
著者:: Nash, P, 等
出版事項: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
著者:: Nash, P, 等
出版事項: (2018)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
著者:: Alison O’Mahony, 等
出版事項: (2018-06-01)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
著者:: Tsutomu Takeuchi, 等
出版事項: (2021-08-01)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
著者:: Roy Fleischmann, 等
出版事項: (2022-12-01)

Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
著者:: Nash, P, 等
出版事項: (2020)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
著者:: Mease, P, 等
出版事項: (2018)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2020)

Methotrexate in psoriasis and psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
著者:: Gladman, DD, 等
出版事項: (2022)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
著者:: Helliwell, P, 等
出版事項: (2018)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
著者:: Coates, L, 等
出版事項: (2021)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
著者:: Nash, P, 等
出版事項: (2018)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
著者:: de Vlam, K, 等
出版事項: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
著者:: Peter Nash, 等
出版事項: (2018-11-01)

Precision drug delivery through methotrexate and tofacitinib citrate encapsulated mesoporous silica scaffold
著者:: Dinesh Chakole, 等
出版事項: (2024-06-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
著者:: Dougados, M, 等
出版事項: (2020)

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
著者:: Dafna D. Gladman, 等
出版事項: (2024-12-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
著者:: Dafna D. Gladman, 等
出版事項: (2022-02-01)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
著者:: Philip J. Mease, 等
出版事項: (2024-01-01)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
著者:: Taylor, P, 等
出版事項: (2019)

Psoriatic arthritis - Tofacitinib as a new treatment
著者:: Marta Skorupska, 等
出版事項: (2024-06-01)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
著者:: Alexis Ogdie, 等
出版事項: (2024-09-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
著者:: Philip J Mease, 等
出版事項: (2019-06-01)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
著者:: Philip J. Mease, 等
出版事項: (2023-08-01)

Fate of lymphocytes after withdrawal of tofacitinib treatment.
著者:: Elisa Piscianz, 等
出版事項: (2014-01-01)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
著者:: Mease, PJ, 等
出版事項: (2019)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
著者:: Ana-Maria Orbai, 等
出版事項: (2022-09-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
著者:: Dougados, M, 等
出版事項: (2022)

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
著者:: Adrian Ciurea, 等
出版事項: (2023-09-01)

Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis
著者:: Yan Gao, 等
出版事項: (2023-05-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
著者:: Maxime Dougados, 等
出版事項: (2022-11-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
著者:: Laura C. Coates, 等
出版事項: (2021-03-01)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2018)

Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy
著者:: Rattanakaemakorn P, 等
出版事項: (2021-05-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
著者:: Lars E. Kristensen, 等
出版事項: (2023-02-01)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
著者:: Philip J Mease, 等
出版事項: (2019-06-01)

Tofacitinib
著者:: Nilgün Şentürk
出版事項: (2022-04-01)